Boundless Bio has unveiled promising preclinical data for its lead ecDNA-directed therapy, BBI-940, at the AACR Annual Meeting 2026. This innovative treatment targets a newly identified kinesin protein, crucial for the segregation and inheritance of extrachromosomal DNA (ecDNA) in cancer cells, while being non-essential in healthy cells. BBI-940, a first-in-class oral Kinesin degrader, is currently undergoing evaluation in the Phase 1 KOMODO-1 trial for patients with advanced or metastatic ER+/HER2- breast cancer and triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR).

The significance of this development lies in the role of ecDNA in promoting chromosomal instability, which is linked to oncogene amplification and therapeutic resistance. Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio, emphasized that the selective degradation of Kinesin led to ecDNA mis-segregation, depletion, and reduced viability of ecDNA-positive cancer cells. In preclinical models, BBI-940 demonstrated robust antitumor activity, particularly in ecDNA-positive breast cancer models, indicating its potential to address a critical unmet need in treating high-risk oncogene amplified tumors.

The implications of this research extend to redefining therapeutic strategies for cancers characterized by ecDNA. By targeting a specific dependency in these tumors, BBI-940 could shift the current paradigms in drug development, particularly for those cancers that have proven resistant to conventional therapies. This approach not only highlights the therapeutic potential of targeting mitotic machinery in cancer but also sets a precedent for the development of ecDNA-directed therapies, potentially accelerating timelines for bringing innovative treatments to clinical practice.

Source: globenewswire.com